

104. (New) An isolated antibody or binding fragment thereof which binds to a TGF-beta binding protein, wherein said binding protein is selected from the group consisting of:

(a) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, or a complementary sequence thereto, and

(b) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 10, 12, 14, and 16.

E1 105. (New) An isolated antibody or binding fragment thereof which binds to a TGF-beta binding protein, wherein said binding protein is selected from the group consisting of:

(a) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, or a complementary sequence thereto;

(b) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 10, 12, 14, and 16; and

(c) a polypeptide encoded by a polynucleotide having at least 90% identity with a full length sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, or a complementary sequence thereto.

106. (New) The antibody of claim 105 wherein the polypeptide of (c) specifically binds to at least a human bone morphogenic protein selected from the group consisting of bone morphogenic protein 5 and bone morphogenic protein 6.

REMARKS

Reconsideration of the present Application in view of the above amendments and the following remarks is respectfully requested. Claims 94-103 were pending in this application and new claims 104-106 have been added by amendment herewith, such that claims 94-106 are currently pending. Support for the new claims may be found in the specification, for example, at